Ponatinib may make allogeneic hematopoietic stem cell transplantation unnecessary for CML-BC under specific conditions, such as de novo cases: a case series of de novo CML-BC treated with ponatinib and no transplantation.

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia & Lymphoma Pub Date : 2025-06-25 DOI:10.1080/10428194.2025.2521646

Sukenao Koyabu, Takashi Onaka, Kazunori Imada

引用次数: 0

查看原文本刊更多论文

在特定情况下，波纳替尼可能使CML-BC不需要移植同种异体造血干细胞，例如新发病例：波纳替尼治疗的CML-BC新发病例系列，未移植。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia & Lymphoma 医学-血液学

CiteScore

4.10

自引率

3.80%

发文量

384

审稿时长

1.8 months

期刊介绍： Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor